Quest Diagnostics Acquires Fresenius Medical Care's Spectra Assets

Quest Diagnostics has announced an agreement to acquire select laboratory assets from Fresenius Medical Care's Spectra Laboratories, expanding Quest's portfolio to include dialysis-related water testing and services for end-stage kidney disease. The acquisition is part of Fresenius's ongoing strategic turnaround and portfolio optimization plan aimed at divesting non-core assets to enhance operational efficiencies. Under the agreement, Quest will provide comprehensive laboratory services for dialysis centers operated by Fresenius and its partners in the U.S., which is expected to improve the speed of test results and clinical outcomes. Fresenius CEO Helen Giza highlighted that this transaction aligns with their focus on core business and sustainable growth. Financial terms of the deal were not disclosed, and the acquisition is anticipated to close in the second half of 2025. The transition of services is expected to be finalized by early 2026.